

# Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

https://marketpublishers.com/r/C8A78FE0EE9EN.html

Date: May 2016

Pages: 74

Price: US\$ 335.00 (Single User License)

ID: C8A78FE0EE9EN

## **Abstracts**

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting CD20 in comparison with originator anti-CD20 antibodies to treat solid tumors as well as inflammatory diseases as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of CD20 targeting biosimilar and biosuperior antibodies for treatment of hematologic malignancies, rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies.

Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,

Class of Compound,

Company,



	Pro	odu	ct (	Cate	gory,
--	-----	-----	------	------	-------

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



## **Contents**

#### 1. 2015 SALES OF ANTI-CD20 ANTIBODIES

#### 2. ORIGINATOR ANTI-CD20 ANTIBODIES

Rituxan/MabThera Approved Indications & Pipeline Gazyva Approved Indications & Pipeline Arzerra Approved Indications and R&D Pipeline Zevalin Approved Indications

#### 3. BIOSUPERIOR ANTI-CD20 ANTIBODIES

3RD GENERATION ANTI-CD20 ANTIBODIES
Bispecific Anti-CD20 Antibodies
Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines

#### 4. BIOSIMILAR ANTI-CD20 ANTIBODIES

Rituxan/MabThera Biosimilar Antibodies:
Developments in Regulated Markets
Developments in Less Regulated Markets
Arzerra Biosimilar Antibodies

### 5. CORPORATE ANTI-CD20 BIOSIMILAR & BIOSUPERIOR ANTIBODY PIPELINES



#### I would like to order

Product name: Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

Product link: <a href="https://marketpublishers.com/r/C8A78FE0EE9EN.html">https://marketpublishers.com/r/C8A78FE0EE9EN.html</a>

Price: US\$ 335.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/C8A78FE0EE9EN.html">https://marketpublishers.com/r/C8A78FE0EE9EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970